The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma.

Meredith  McKean

Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)

Research Funding - Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)

David Henry  Aggen

Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Seagen

Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign

Nehal J.  Lakhani

Consulting or Advisory Role - Ikena Oncology; Innovent Biologics; SK Life Sciences

Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Celgene (Inst); Celgene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Formation Biologics (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics; Innovent Biologics (Inst); Jounce Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)

Babar  Bashir

Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Ikena Oncology (Inst); KAHR Medical (Inst); Merck (Inst); RasCal (Inst); Syros Pharmaceuticals (Inst); Tarveda Therapeutics (Inst)

Jason J.  Luke

Stock and Other Ownership Interests  - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics

Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Astellas Pharma; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; Eisai; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Mersana; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; Spring Bank; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics

Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)

Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)

Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics

Jean H.  Hoffman-Censits

Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech

Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech; Seagen

Research Funding - Foundation Medicine; Genentech; Sanofi

Travel, Accommodations, Expenses - Roche/Genentech

Omar  Alhalabi

Consulting or Advisory Role - Seagen

Isaac Alex  Bowman

Consulting or Advisory Role - AstraZeneca/Merck; Dendreon; Foundation Medicine; Janssen Biotech; Janssen Biotech; Seattle Genetics/Astellas

Speakers' Bureau - Caris Life Sciences

Elizabeth A.  Guancial

No Relationships to Disclose

Alan  Tan

Stock and Other Ownership Interests  - Adaptimmune; Aprea AB; Bluebird Bio; crispr therapeutics; Editas Medicine; FATE Therapeutics; Geron; Iovance Biotherapeutics; Jounce Therapeutics; MEI Pharma; Myovant Sciences; Nektar; Sangamo Therapeutics

Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Verastem

Consulting or Advisory Role - Exelixis; Foundation Medicine

Speakers' Bureau - AstraZeneca; bristol myers squibb; verastem

Trupti  Lingaraj

Employment - Epizyme; Ikena Oncology

Stock and Other Ownership Interests  - Epizyme; Ikena Oncology

Marissa  Timothy

Employment - Ikena Oncology

Katherine  Kacena

Consulting or Advisory Role - BioBridges

Karim S.  Malek

Employment - Ikena Oncology; Takeda

Travel, Accommodations, Expenses - Takeda

Other Relationship - Takeda

Sergio  Santillana

Employment - ARIAD; Ikena Oncology; Merrimack; SLSS Consulting LLC

Leadership - ARIAD; Ikena Oncology; Merrimack; SLSS Consulting LLC

Stock and Other Ownership Interests  - ARIAD; Ikena Oncology; Merrimack

Consulting or Advisory Role - Akamara Therapeutics; Clarus Ventures; Ikena Oncology; Kyn Therapeutics; Northern Biologics; Partners Therapeutics; YourEncore; Yumanity Therapeutics

Patents, Royalties, Other Intellectual Property - Patent related to work in Takeda (2015-2016) submitted for approval

Travel, Accommodations, Expenses - Akamara Therapeutics; ARIAD; Ikena Oncology; Merrimack